Vyleesi (Bremelanotide) at 65 and Older: Activity, Safety, and What You Need to Know

What Vyleesi Actually Does, and Why Age Matters

Bremelanotide works by activating melanocortin receptors, specifically MC3R and MC4R, in the central nervous system to increase sexual desire. It does not act on hormones directly. The FDA approved it in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

That approval matters for you if you are over 65, because the label does not include postmenopausal women. The two key Phase III trials, RECONNECT Study 1 and Study 2, enrolled women aged 18 to 55, with a mean age of approximately 37 years. Fewer than 2% of participants were over 55, and the FDA prescribing information states that clinical studies did not include sufficient numbers of women aged 65 and older to determine whether they respond differently from younger women.

That evidence gap is real, and you deserve to know it exists before making any decision.

Why the Evidence Gap Exists

Women over 65 have historically been excluded from sexual-health clinical trials, partly because HSDD was long considered a disorder of reproductive-age women and partly because trials used "premenopausal" as a blanket enrollment criterion. This exclusion reflects a systemic bias rather than evidence that bremelanotide is ineffective or inappropriate in older women.

HSDD does not disappear at menopause. Estimates suggest 12 to 19 percent of postmenopausal women meet criteria for HSDD, and sexual desire distress persists well into the seventh and eighth decades of life.

How the Postmenopausal Body Processes Bremelanotide Differently

Bremelanotide is metabolized primarily through enzymatic hydrolysis rather than cytochrome P450 pathways, which means typical age-related CYP450 changes affect it less than they affect many other drugs. However, several age-related physiologic shifts still matter:

• Renal clearance declines with age. Bremelanotide and its metabolites are renally excreted. The prescribing information recommends avoiding use in severe renal impairment (eGFR <30 mL/min).
• Body composition shifts. Lower lean muscle mass and higher fat-to-lean ratio in postmenopausal women may alter volume of distribution, potentially prolonging the time to peak or extending effect duration, though pharmacokinetic studies specifically in women over 65 have not been published.
• Estrogen deficiency changes vascular reactivity. The postmenopausal vascular environment is less protected from adrenergic surges, which may amplify bremelanotide's known transient hypertensive effect.

The Blood Pressure Question: What You Need to Know Before Injecting

This is the most important safety signal for women over 65, and it is worth treating seriously.

In Phase III trials, bremelanotide caused a mean transient increase of approximately 6 mmHg in systolic blood pressure and 3 mmHg in diastolic blood pressure peaking within 4 hours of injection and generally resolving by 12 hours. In younger, otherwise healthy trial participants, this was tolerable. In a 68-year-old woman with baseline hypertension or subclinical atherosclerosis, the picture changes.

The FDA label carries a specific warning against use in women with cardiovascular disease, uncontrolled hypertension, or high cardiovascular risk. These conditions cluster heavily in the over-65 population.

What Counts as High Cardiovascular Risk

Your clinician should assess your 10-year ASCVD risk using the Pooled Cohort Equations before prescribing bremelanotide. The American Heart Association considers a score of 7.5% or higher as elevated. Most women over 65 without prior cardiovascular events will have a 10-year ASCVD risk above 7.5% simply by virtue of age, which means the majority of women in this age group technically fall under the label's caution zone.

This does not mean bremelanotide is automatically off the table, but it does mean that prescribing it without a cardiovascular assessment first is not appropriate practice.

Monitoring Your Blood Pressure at Home

If your clinician decides that a trial of bremelanotide is reasonable for you, home blood pressure monitoring on each day you use it is a practical step. Check your baseline before the injection, then again at 4 hours and at 12 hours. If systolic blood pressure rises above 160 mmHg or you experience headache, chest tightness, or visual changes, do not use it again before speaking with your clinician.

Nausea, Dizziness, and the Fall Risk No One Talks About

Nausea occurred in approximately 40% of participants in the RECONNECT trials, making it the most common adverse effect. Vomiting occurred in 4 to 6% of users. Flushing and dizziness were also reported in more than 10% of participants.

For a 35-year-old, dizziness after an injection is an inconvenience. For a 70-year-old woman, dizziness plus nausea in a bathroom or bedroom environment is a fall risk with real injury consequences. Hip fractures in women over 65 carry a one-year mortality rate of approximately 20%.

Practical Steps to Reduce Fall Risk

• Inject while seated or lying down, not standing.
• Stay in a horizontal or semi-reclined position for at least 30 to 60 minutes after injection.
• Keep the area free of rugs, cords, or obstacles before injecting.
• Have a glass of water nearby. Staying hydrated blunts nausea severity for some users.
• If dizziness is significant after a first dose, discuss with your clinician whether a reduced injection cadence or pre-treatment with an antiemetic (such as ondansetron) is appropriate.

The prescribing information does not formally address this fall-risk scenario because the trial population was younger, but applying standard geriatric safety principles here is straightforward clinical reasoning.

Activity Restrictions and Physical Exercise After Injection

No published guideline or trial has specifically studied the interaction between bremelanotide injection and physical activity in women over 65. The following framework is drawn from the known pharmacodynamics of the drug and standard cardiovascular physiology. It represents a clinical reasoning approach developed by the WomanRx editorial team and reviewed by a board-certified clinician, not a specific published protocol.

The 12-Hour Activity Window

Because bremelanotide's blood pressure effect peaks within 4 hours and resolves within approximately 12 hours, that 12-hour window is the period of greatest concern for activity modification.

Activities to avoid in the first 12 hours after injection:

• High-intensity interval training or any exercise that substantially raises your heart rate above 70% of maximum
• Heavy resistance training or lifting
• Hot yoga or any sustained heat exposure (saunas, hot tubs), which adds vasodilatory and cardiovascular load
• Swimming or water-based exercise where dizziness could be dangerous

Activities that are generally reasonable after the first 12 hours:

• Walking at a comfortable pace
• Gentle stretching or restorative yoga
• Low-impact water aerobics
• Light resistance work with bands or light weights

Activities that carry low concern at any time point, assuming you feel well:

• Seated activities such as reading, light craft work, or computer use
• Short, slow walks to the bathroom or kitchen in the immediate post-injection period

Why Heat Matters Specifically

The flushing that bremelanotide causes involves peripheral vasodilation. Adding external heat through exercise, hot showers, or hot tubs stacks vasodilatory signals and may cause a more pronounced drop in standing blood pressure, which increases dizziness and syncope risk. For women over 65 who already have some degree of age-related autonomic dysfunction, this stacking effect is not trivial.

Driving and Operating Machinery

The prescribing information advises against driving for 12 hours after each injection due to possible dizziness. This applies regardless of age but is particularly relevant for older women who may have slower reflexes or reduced visual acuity that compounds dizziness-related impairment.

Sexual Activity Itself: Timing and Positioning Considerations

Bremelanotide is injected approximately 45 minutes before anticipated sexual activity. The desired effect, increased desire, occurs in that window. The blood pressure effect also occurs in that window. This means that sexual activity and peak cardiovascular effect overlap.

For women with known coronary artery disease or heart failure, the exertion of sexual activity itself is a cardiovascular stress. Adding bremelanotide's blood pressure effect on top of that exertion has not been studied. The American Heart Association's guidance on sexual activity after cardiac events, while not specific to bremelanotide, provides a useful reference frame: women who can walk briskly for 10 minutes without symptoms are generally considered at low cardiac risk for sexual activity. The AHA recommends discussing sexual activity readiness with a cardiologist after any major cardiac event.

If your cardiac status is uncertain, a cardiology clearance before starting bremelanotide is reasonable practice.

Pregnancy, Lactation, and Contraception

Postmenopausal women (defined as 12 consecutive months without a menstrual period) are not at risk for pregnancy, so the pregnancy considerations below apply primarily to perimenopausal women in their early to mid-60s who may still have occasional menstrual cycles.

Pregnancy Safety

Bremelanotide is classified as having no adequate and well-controlled studies in pregnant women. Animal reproduction studies showed adverse effects on fetal development at doses above the clinical dose. The drug should not be used during pregnancy. Because HSDD is diagnosed in reproductive-age and perimenopausal women who may still ovulate intermittently, effective contraception is required during use.

If you are in your early 60s and not yet confirmed postmenopausal, a negative pregnancy test is recommended before starting treatment. Hormonal contraception or non-hormonal barrier methods are appropriate.

Lactation

Bremelanotide has not been studied in lactating women. The prescribing information recommends avoiding use during breastfeeding. Postmenopausal women do not breastfeed, but this is relevant for any perimenopausal woman still nursing an older infant or engaging in any lactation.

Contraception Interaction

Bremelanotide may transiently reduce the absorption of orally administered drugs taken within 1 hour of injection due to decreased gastric motility. If you take a daily oral contraceptive pill and are perimenopausal, take it at least 1 hour before or after the injection to avoid reduced absorption.

Who This Drug May Be Right For (and Who It Is Not)

Potentially appropriate, with careful clinician assessment:

• Women over 65 in confirmed good cardiovascular health (10-year ASCVD risk <7.5%, normal baseline blood pressure, no history of cardiac events) who have significant HSDD causing personal distress
• Women who have tried and not responded to psychosexual therapy, relationship counseling, or genitourinary syndrome of menopause treatment and still report low desire as a separate concern
• Women who understand this is off-label use with limited age-specific safety data and give informed consent accordingly

Not appropriate for:

• Women with uncontrolled hypertension (systolic >140 mmHg at baseline)
• Women with known cardiovascular disease, including coronary artery disease, heart failure, or prior stroke
• Women with severe renal impairment (eGFR <30 mL/min)
• Women taking multiple antihypertensive agents whose blood pressure control may be disrupted by the transient pressor effect
• Women with a history of significant nausea or vomiting disorders where additional emetic burden would be poorly tolerated
• Women whose low desire is primarily explained by genitourinary syndrome of menopause (GSM) or dyspareunia, where local estrogen or ospemifene addresses the root cause more directly

Genitourinary Syndrome of Menopause: Rule This Out First

Before any clinician prescribes bremelanotide to a woman over 65, genitourinary syndrome of menopause (GSM) should be assessed and, if present, treated first. GSM affects up to 84% of postmenopausal women and causes vaginal dryness, burning, dyspareunia, and reduced arousal that can mimic or worsen desire complaints.

The Menopause Society (formerly NAMS) recommends vaginal estrogen as a first-line treatment for GSM and notes that many women report improvement in sexual desire once pain and dryness are resolved. Treating GSM before attributing low desire to a central desire deficit avoids exposing women to a drug with real cardiovascular side effects when the underlying issue is peripheral and treatable with a topical preparation.

What the Research Actually Shows: RECONNECT and Its Limits

The two RECONNECT Phase III trials enrolled a combined total of approximately 1,247 premenopausal women with generalized, acquired HSDD. The primary outcome was change in the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13. Bremelanotide showed a statistically significant improvement in both measures compared to placebo, with a mean improvement of 0.5 points on the FSFI desire subscale (on a 1 to 6 scale) and a 0.3-point improvement on the distress item.

The effect size was modest. About 25% of treated women achieved a clinically meaningful response compared to about 17% on placebo. That means a number-needed-to-treat of roughly 12, meaning 12 women need to try the drug for one additional woman to benefit beyond what placebo would achieve.

These numbers were generated in a population with a mean age of 37. Extrapolating them to a 70-year-old woman requires acknowledging that the central melanocortin system does change with age, that estrogen deficiency may alter receptor sensitivity, and that the placebo response rate in older populations with different psychological and relational contexts may differ substantially. None of this has been directly studied.

As WomanRx medical reviewer Elena Vasquez, MD notes: "The modest effect size in younger premenopausal women, combined with the complete absence of controlled trial data in women over 65, means we are making a clinical judgment call for this age group based on mechanism and pharmacology, not outcomes data. That requires a very thorough informed consent conversation about what we know and what we genuinely do not."

Practical Injection Technique for Older Women

Bremelanotide comes as a single-use autoinjector for subcutaneous injection into the abdomen or thigh. The autoinjector design requires moderate hand strength and manual dexterity. Women with arthritis, reduced grip strength, or tremor may find self-injection more difficult.

Tips for injecting with reduced hand strength:

• Use your non-dominant thigh rather than the abdomen if abdominal pinching is difficult.
• Rest the autoinjector firmly against the skin before activating to reduce the force needed.
• Ask a clinician or nurse to demonstrate the injector technique in person before your first home use.
• Check whether your pharmacy includes a training device.

Store unused autoinjectors at room temperature (up to 77°F / 25°C). Do not freeze. Each autoinjector is single-use only.

Drug Interactions Relevant to Women Over 65

Polypharmacy is common after 65. Relevant interactions for bremelanotide include:

• Antihypertensives: Additive blood pressure effects are theoretically possible, though the direction is complex because bremelanotide raises blood pressure transiently while antihypertensives lower it chronically. The net effect is unpredictable and requires monitoring.
• Naltrexone: Bremelanotide's efficacy may be reduced by opioid antagonists, including naltrexone, because melanocortin signaling interacts with opioid receptor pathways.
• Orally administered drugs: As noted above, reduced gastric motility in the hour after injection may reduce absorption of drugs taken within that window. This includes oral contraceptives, thyroid medications, and some antihypertensives.

Bring a complete medication list to any appointment where bremelanotide is being considered.